Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...910111213141516171819...7475»
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Journal:  Adult Eye Conditions: Diabetic Retinopathy and Age-Related Macular Degeneration. (Pubmed Central) -  Aug 18, 2022   
    Smoking cessation should be recommended for patients with AMD who smoke. For patients with wet, or neovascular, AMD, first-line therapy is an intravitreal anti-VEGF drug (ie, ranibizumab, bevacizumab, aflibercept [Eylea]).
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Prognostic Evaluation of Vitrectomy Assisted by Lucentis in Diabetic Retinopathy and Neovascular Glaucoma. (Pubmed Central) -  Aug 13, 2022   
    Therefore, the study reached the following conclusions about vitrectomy assisted by Lucentis: (1) it effectively increases the success rate of treatment, decreases postoperative complications as well as surgical risks, and improves patients' vision; (2) it promotes the recovery of IOP, reduces macular edema and VEGF levels in aqueous humor, and inhibits the neonatal formation of blood vessels. It is finally confirmed that Lucentis adjuvant PPV in the treatment of DR complicated with NVG is safe and feasible.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Review, Journal:  Clinical implications of retinal oximetry in retinal vein occlusion: a review. (Pubmed Central) -  Aug 13, 2022   
    It is finally confirmed that Lucentis adjuvant PPV in the treatment of DR complicated with NVG is safe and feasible. The current literature on retinal oxygenation in ischaemic subtypes of RVO and in drug therapies is minimal, and further work is required to expand upon our understanding of how ischaemia and drugs influence retinal oxygenation and clinical outcomes.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Eylea (aflibercept intravitreal) / Bayer, Regeneron
    Enrollment change, Trial withdrawal:  BEY-RAP: Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation (clinicaltrials.gov) -  Aug 10, 2022   
    P4,  N=0, Withdrawn, 
    Enrolling by invitation --> Completed N=30 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Legal obligation in the general population: face mask influence on endophthalmitis after intravitreal injection. (Pubmed Central) -  Aug 7, 2022   
    Although some potential confounders (wearing time, skin flora) could not be considered, there was no clear signal that the introduction of compulsory face masking in public life did alter the risk for PIE in our patient population. Three and six months after PIE, no difference in visual acuity was detectable between the two study periods.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  The Effect of Sample Medication Use on Subsequent Anti-VEGF Agent Selection for Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Aug 6, 2022   
    Our study found that eyes receiving a sample anti-VEGF agent (ranibizumab or aflibercept) for their initial injection were less likely to receive bevacizumab at future visits relative to eyes that did not receive an anti-VEGF sample, even after one year of treatment. Given the persistent use of more expensive medications at subsequent injections for patients who were initiated on samples, insurance payors may consider waiving PA requirements for bevacizumab to avoid a paradoxical increase in health-care costs.
  • ||||||||||  Axpaxli (intravitreal axitinib implant) / Ocular Therap
    Enrollment closed:  CLN-0046: Treatment of AMD Subjects With OTX-TKI (clinicaltrials.gov) -  Aug 3, 2022   
    P1,  N=29, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Prevalence and Clinical Implications of Subretinal Fluid in Retinal Diseases: A real-world cohort study (Halifax Convention Centre -C2) -  Jul 31, 2022 - Abstract #COS2022COS_484;    
    Baseline SRF is a good marker for a greater reduction in CST in both DME and RVO, but an improvement in VA associated with SRF may be only noted in DME. The presence of SRF may have significant clinical implications on patients undergoing therapy, and it may be used in clinical decision making for ophthalmologists treating DME and RVO.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Review, Journal:  Treat and extend regimen for diabetic macular oedema-a systematic review and meta-analysis. (Pubmed Central) -  Jul 31, 2022   
    However, the T&E approach offers the potential for fewer patient visits, thereby reducing treatment burden. Longer term studies on T&E with a standardised protocol would be required to assess the longevity of the vision gain in the first year despite a likely reduced treatment burden compared to the PRN trials.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Outcomes after switching eyes that were stable on aflibercept to ranibizumab versus continuing aflibercept in neovascular age-related macular degeneration. (Pubmed Central) -  Jul 30, 2022   
    In vitrectomy for PDR, preoperative IVR can significantly reduce surgery time and lower the incidence of intraoperative bleeding, intraocular electrocoagulation use, iatrogenic retinal breaks, relaxing retinotomy and silicone oil tamponade during surgery and gain short-term better postoperative BCVA and thinner CRT. nAMD eyes that were stable or improving on aflibercept but were switched to ranibizumab worsened, while those in a comparable group maintained on aflibercept remained fairly stable, suggesting a potential efficacy difference between the two drugs.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal:  Macular neovascularization lesion type and vision outcomes in neovascular age-related macular degeneration: post hoc analysis of HARBOR. (Pubmed Central) -  Jul 30, 2022   
    P3
    nAMD eyes that were stable or improving on aflibercept but were switched to ranibizumab worsened, while those in a comparable group maintained on aflibercept remained fairly stable, suggesting a potential efficacy difference between the two drugs. Differences in BCVA outcomes between CONAN lesion type subgroups support the use of an anatomic classification system to characterize MNV and prognosticate visual responses to anti-vascular endothelial growth factor therapy for nAMD.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, Lucentis (ranibizumab) / Roche, Novartis
    Preclinical, Journal:  Beovu, but not Lucentis impairs the function of the barrier formed by retinal endothelial cells in vitro. (Pubmed Central) -  Jul 30, 2022   
    Interestingly, polysorbate-80-component of Beovu-but not polysorbate-20-in Lucentis-slightly, but significantly lowered the cell index, also associated with reduced claudin-1 expression. In summary, our results indicate that Beovu changes the behavior of retinal endothelial cells, thus providing an alternative "non-immunological" explanation for the most relevant of observed side effects.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Genetic Polymorphisms in VEGFR Coding Genes (FLT1/KDR) on Ranibizumab Response in High Myopia and Choroidal Neovascularization Patients. (Pubmed Central) -  Jul 28, 2022   
    In the association study of genotypes in FLT1 with the response to ranibizumab, we found a significant association between two FLT1 variants (rs9582036, rs7993418) with ranibizumab efficacy at the 12-month follow-up. About the KDR gene, we found that two KDR variants (rs2305948, rs2071559) are associated with best-corrected visual acuity (BCVA) improvement and KDR (rs2239702) is associated with lower rates of BCVA worsening considering a 12-month follow-up period.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review. (Pubmed Central) -  Jul 28, 2022   
    In conclusion, it is advised that intravitreal anti-VEGF should be used as the first-line treatment for zone I ROP while laser therapy should be the mainstay for zone II ROP owing to the different pathogenetic mechanisms. In patients with recurrence after initial anti-VEGF injection, that given ranibizumab may opt to repeat the injection while that given bevacizumab should consider supplement laser ablative treatment.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal, HEOR:  The effects of loading ranibizumab on vision-related quality of life in the treatment of low-risk neovascular age-related macular degeneration. (Pubmed Central) -  Jul 27, 2022   
    General vision (p < 0.001), ocular pain (p = 0.025), near activities (p < 0.001), distance activities (p = 0.027), vision-specific mental health (p = 0.014), vision-specific role difficulties (p < 0.001), and peripheral vision (p = 0.046) were significantly higher after the treatment. NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Twelve-month outcomes of ranibizumab versus aflibercept for macular oedema in branch retinal vein occlusion: data from the FRB! registry. (Pubmed Central) -  Jul 27, 2022   
    NEI VFQ-25 TR is a useful questionnaire for evaluating changes in visual functions and psychosocial characteristics of low-risk neovascular AMD patients before and after the injections. Visual outcomes at 12 months in this direct comparison of ranibizumab and aflibercept for BRVO in real-world practice were generally good and similar for the 2 drugs, despite a greater effect of aflibercept on CST and time to first grading of inactivity.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis, Macugen (pegaptanib) / Bausch Health
    Journal:  Angiogenic footprints in diabetic retinopathy: opportunities for drug development. (Pubmed Central) -  Jul 26, 2022   
    4 widely explored drugs being-Bevacizumab, pegaptanib sodium, ranibizumab, and aflibercept. The review article tries to summarize studies illustrating the efficacy of these drugs in the treatment of diabetic retinopathy along with some of the herbal therapeutic paradigms displaying anti-angiogenic action that is being used to treat this condition.
  • ||||||||||  TAB014 / TOT Biopharm
    New P3 trial:  nAMD: TAB014 Compared to Lucentis (clinicaltrials.gov) -  Jul 18, 2022   
    P3,  N=488, Recruiting, 
  • ||||||||||  Susvimo (ranibizumab port delivery system) / Roche
    SUSVIMO Pre-Case Training (Javits Center, Level 4, Room 405.3) -  Jul 18, 2022 - Abstract #ASRS2022ASRS_2;    
    This training does not qualify for CME credits. This program is not affiliated with ASRS.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Review, Journal:  Long-term outcomes of anti-VEGF therapy for macular edema in retinal vein occlusion (Pubmed Central) -  Jul 16, 2022   
    Their results helped identify the main aspects of antiangiogenic therapy that could improve the treatment outcomes for patients with RVO. Additionally, the article discusses the predictive factors for therapy outcomes and the effect of anti-VEGF therapy on the development of neovascular complications in patients with ischemic RVO.